Abraham Salacata, MD
Cardiovascular Disease · Alpena, MINPI 1255440095
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (51.5%), travel and lodging and education — rather than concentrated in one kind of arrangement. 24 manufacturers reported payments, led by Medtronic at 26.9% of the total.
Across 209 payments — averaging $39.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$2K
- Abbott$2K
- Boston Scientific$1K
- Novartis$493
- Johnson & Johnson$461
- Actelion Pharmaceuticals US, Inc.$432
- plus $2K from 18 others
Across 266 payments — averaging $671.23 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boehringer Ingelheim International GmbH$79K
- Boehringer Ingelheim Pharma GmbH & Co.kg$51K
- Amgen$16K
- Novartis$9K
- Bayer$9K
- AstraZeneca$7K
- plus $7K from 2 others
What the payments were for
- Travel & lodging$3,93347%
- Food & beverage$4,29652%
- Education$1131%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 9 | $2,248 |
| Abbott | 23 | $1,638 |
| Boston Scientific | 16 | $1,141 |
| Novartis | 32 | $493 |
| Johnson & Johnson | 19 | $461 |
| Actelion Pharmaceuticals US, Inc. | 20 | $432 |
| AstraZeneca | 19 | $369 |
| Pfizer | 14 | $311 |
| E.r. Squibb & Sons, L.L.C. | 17 | $296 |
| Abiomed | 3 | $153 |
| Amgen | 5 | $134 |
| Cvrx, Inc. | 1 | $132 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 7 | $115 |
| Merck | 6 | $85 |
| Boehringer Ingelheim | 4 | $81 |
| Amarin Pharma, Inc. | 4 | $53 |
| W. L. Gore & Associates, Inc. | 1 | $42 |
| Scpharmaceuticals Inc. | 2 | $35 |
| Alnylam Pharmaceuticals Inc. | 2 | $29 |
| Kestra Medical Technology Services, Inc. | 1 | $26 |
| Sanofi-aventis U.S. LLC | 1 | $21 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $20 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $15 |
| Cook Medical LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Micra$1,459
- AVEIR$959
- GENERAL - THERAPIES$672
- EVERA MRI XT DR SURESCAN$662
- Barostim Neo System$132
- XARELTO$125
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$114
How this compares
$8,342 in reported general payments places this provider in the 70th percentile of 760 cardiovascular disease providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AdempasRiociguat | 51 | $710,923 |
| OpsumitMacitentan | 55 | $679,938 |
| UptraviSelexipag | 11 | $165,327 |
| EliquisApixaban | 107 | $117,778 |
| EntrestoSacubitril/Valsartan | 35 | $50,031 |
| JardianceEmpagliflozin | 61 | $47,226 |
| FarxigaDapagliflozin Propanediol | 26 | $31,883 |
| Metoprolol Succinate | 56 | $1,189 |
| Carvedilol | 52 | $1,104 |
| Potassium Chloride | 26 | $1,065 |
| Isosorbide Dinitrate | 15 | $989 |
| Bumetanide | 16 | $781 |
| Atorvastatin Calcium | 42 | $685 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 14 | $659 |
| Rosuvastatin Calcium | 16 | $608 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Opsumit, Uptravi | $432 | $845,26566 claims |
| PfizerEliquis | $311 | $117,778107 claims |
| NovartisEntresto | $493 | $50,03135 claims |
| Boehringer IngelheimJardiance | $81 | $47,22661 claims |
| AstraZenecaFarxiga | $369 | $31,88326 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 760 cardiovascular disease providers in Michigan.
Other cardiovascular disease in Alpena
- Marschall RungeAnn Arbor$1.8M
- Jihad MustaphaGrand Rapids$1.6M
- Vallerie McLaughlinAnn Arbor$947K
- Pedro Villablanca SpinettoDetroit$620K
- Stanley ChetcutiAnn Arbor$573K
- David HainesRoyal Oak$492K
- Steven AlmanyTroy$471K
- David StroblLansing$445K
- Herman KadoSouthfield$442K
- Douglas HorstmanshofRoyal Oak$407K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.